English
简体中文
Total: £ 56.28
Published Date: 2026-03-24 | Pages: 115 | Tables: 115 | Pharma & Healthcare
The global mRNA Drug market was valued at US$ 448 million in 2025 and is anticipated to reach US$ 627 million by 2032, at a CAGR of 5.0% from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on mRNA Drug competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
In 2025, global mRNA therapeutics production capacity is about 2,250,000 doses, with actual production reaching approximately 1,750,000 doses. The average global market price is around US$ 320 per dose. The market gross margin mainly ranges between 55% and 75%. mRNA therapeutics are a class of biopharmaceutical products that use messenger RNA (mRNA) molecules to instruct cells to produce specific proteins for therapeutic purposes. After delivery into the body, the mRNA sequence enters cells and utilizes the cellular translation machinery to synthesize the encoded protein, which can trigger immune responses, replace missing proteins, or modulate disease-related biological pathways. Unlike traditional drugs that directly supply proteins or chemical compounds, mRNA therapeutics provide genetic instructions that enable cells to produce the therapeutic proteins themselves. These therapies are typically delivered using lipid nanoparticle (LNP) delivery systems to protect the mRNA and facilitate cellular uptake. mRNA therapeutics have been widely studied and developed for vaccines, cancer immunotherapy, protein replacement therapy, and rare disease treatment. Their advantages include rapid development cycles, flexible design, and scalable manufacturing processes.
The upstream of the mRNA therapeutics industry mainly includes nucleoside raw materials, plasmid DNA templates, enzymes used in in vitro transcription, lipid nanoparticle materials, and specialized biochemical reagents. These materials are critical for mRNA synthesis, purification, and formulation processes. The midstream involves mRNA sequence design, in vitro transcription, purification, encapsulation using lipid nanoparticles, formulation development, and large-scale biomanufacturing. Strict quality control and cold-chain logistics are essential to maintain product stability and efficacy. The downstream includes pharmaceutical companies, hospitals, vaccination programs, and clinical treatment systems. Applications span vaccines, oncology therapeutics, infectious disease prevention, and rare disease treatment. The industry also includes supporting services such as contract development and manufacturing organizations (CDMOs), clinical research services, and regulatory consulting.
The mRNA therapeutics market has experienced rapid expansion following the global success of mRNA-based vaccines. The platform’s flexibility and rapid development capability have made it one of the most promising technologies in modern biopharmaceutical innovation. One of the primary growth drivers is the expansion of mRNA technology beyond infectious disease vaccines. Pharmaceutical companies are actively developing mRNA-based cancer immunotherapies, protein replacement therapies, and treatments for rare genetic diseases. These applications significantly broaden the potential market scope of mRNA therapeutics. Another important factor is the continuous improvement of delivery technologies, particularly lipid nanoparticle (LNP) systems. Advances in delivery efficiency and safety are enabling mRNA drugs to target a wider range of tissues and diseases. In addition, increasing investments from governments, biotechnology companies, and venture capital funds are accelerating research and clinical development. As clinical pipelines continue to mature, mRNA therapeutics are expected to play an increasingly important role in the future pharmaceutical landscape.
This report delivers a comprehensive overview of the global mRNA Drug market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding mRNA Drug. The mRNA Drug market size, estimates, and forecasts are provided in terms of sales volume (K Dose) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global mRNA Drug market comprehensively. Regional market sizes by Type, by Application, by Target Cell, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist mRNA Drug manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Moderna
Pfizer
Zydus Cadila
Fosun Pharma
CureVAC
BioNtech
AstraZeneca
Janssen
Segment by Type
Prophylactic Vaccine (Infectious Disease)
Therapeutic Vaccine (Cancer)
Segment by Target Cell
Intramuscular (Dendritic Cell) mRNA
Intravenous (Liver-targeted) mRNA
Intradermal (Skin APC) mRNA
Inhalation (Lung epithelial) mRNA
Segment by Manufacturing Scale
Lab-scale (Preclinical, <1g)
Pilot-scale (Phase I/II, 1-100g)
Commercial-scale (Phase III/Market, >100g)
by Application
Pharmaceutical Companies
Medical Institutions
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Target Cell, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for mRNA Drug manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines mRNA Drug sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 mRNA Drug Market Overview
1.1 Product Definition
1.2 mRNA Drug by Type
1.2.1 Global mRNA Drug Market Value by Type: 2025 vs 2032
1.2.2 Prophylactic Vaccine (Infectious Disease)
1.2.3 Therapeutic Vaccine (Cancer)
1.3 mRNA Drug by Target Cell
1.3.1 Global mRNA Drug Market Value by Target Cell: 2025 vs 2032
1.3.2 Intramuscular (Dendritic Cell) mRNA
1.3.3 Intravenous (Liver-targeted) mRNA
1.3.4 Intradermal (Skin APC) mRNA
1.3.5 Inhalation (Lung epithelial) mRNA
1.4 mRNA Drug by Manufacturing Scale
1.4.1 Global mRNA Drug Market Value by Manufacturing Scale: 2025 vs 2032
1.4.2 Lab-scale (Preclinical, <1g)
1.4.3 Pilot-scale (Phase I/II, 1-100g)
1.4.4 Commercial-scale (Phase III/Market, >100g)
1.5 mRNA Drug by Application
1.5.1 Global mRNA Drug Market Value by Application: 2025 vs 2032
1.5.2 Pharmaceutical Companies
1.5.3 Medical Institutions
1.5.4 Others
1.6 Global mRNA Drug Market Size Estimates and Forecasts
1.6.1 Global mRNA Drug Revenue 2021–2032
1.6.2 Global mRNA Drug Sales 2021–2032
1.6.3 Global mRNA Drug Market Average Price (2021–2032)
1.7 Assumptions and Limitations
2 mRNA Drug Market Competition by Manufacturers
2.1 Global mRNA Drug Sales Market Share by Manufacturers (2021–2026)
2.2 Global mRNA Drug Revenue Market Share by Manufacturers (2021–2026)
2.3 Global mRNA Drug Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of mRNA Drug, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of mRNA Drug, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of mRNA Drug, Product Types and Applications
2.7 Global Key Manufacturers of mRNA Drug, Date of Entry into the Industry
2.8 Global mRNA Drug Market Competitive Situation and Trends
2.8.1 Global mRNA Drug Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global mRNA Drug Players Market Share by Revenue
2.8.3 Global mRNA Drug Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global mRNA Drug Market Scenario by Region
3.1 Global mRNA Drug Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global mRNA Drug Sales by Region: 2021–2032
3.2.1 Global mRNA Drug Sales by Region: 2021–2026
3.2.2 Global mRNA Drug Sales by Region: 2027–2032
3.3 Global mRNA Drug Revenue by Region: 2021–2032
3.3.1 Global mRNA Drug Revenue by Region: 2021–2026
3.3.2 Global mRNA Drug Revenue by Region: 2027–2032
3.4 North America mRNA Drug Market Facts & Figures by Country
3.4.1 North America mRNA Drug Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America mRNA Drug Sales by Country (2021–2032)
3.4.3 North America mRNA Drug Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe mRNA Drug Market Facts & Figures by Country
3.5.1 Europe mRNA Drug Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe mRNA Drug Sales by Country (2021–2032)
3.5.3 Europe mRNA Drug Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific mRNA Drug Market Facts & Figures by Region
3.6.1 Asia Pacific mRNA Drug Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific mRNA Drug Sales by Region (2021–2032)
3.6.3 Asia Pacific mRNA Drug Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America mRNA Drug Market Facts & Figures by Country
3.7.1 Latin America mRNA Drug Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America mRNA Drug Sales by Country (2021–2032)
3.7.3 Latin America mRNA Drug Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa mRNA Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa mRNA Drug Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa mRNA Drug Sales by Country (2021–2032)
3.8.3 Middle East and Africa mRNA Drug Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global mRNA Drug Sales by Type (2021–2032)
4.1.1 Global mRNA Drug Sales by Type (2021–2026)
4.1.2 Global mRNA Drug Sales by Type (2027–2032)
4.1.3 Global mRNA Drug Sales Market Share by Type (2021–2032)
4.2 Global mRNA Drug Revenue by Type (2021–2032)
4.2.1 Global mRNA Drug Revenue by Type (2021–2026)
4.2.2 Global mRNA Drug Revenue by Type (2027–2032)
4.2.3 Global mRNA Drug Revenue Market Share by Type (2021–2032)
4.3 Global mRNA Drug Price by Type (2021–2032)
5 Segment by Application
5.1 Global mRNA Drug Sales by Application (2021–2032)
5.1.1 Global mRNA Drug Sales by Application (2021–2026)
5.1.2 Global mRNA Drug Sales by Application (2027–2032)
5.1.3 Global mRNA Drug Sales Market Share by Application (2021–2032)
5.2 Global mRNA Drug Revenue by Application (2021–2032)
5.2.1 Global mRNA Drug Revenue by Application (2021–2026)
5.2.2 Global mRNA Drug Revenue by Application (2027–2032)
5.2.3 Global mRNA Drug Revenue Market Share by Application (2021–2032)
5.3 Global mRNA Drug Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Moderna
6.1.1 Moderna Company Information
6.1.2 Moderna Description and Business Overview
6.1.3 Moderna mRNA Drug Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Moderna mRNA Drug Product Portfolio
6.1.5 Moderna Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Company Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer mRNA Drug Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Pfizer mRNA Drug Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Zydus Cadila
6.3.1 Zydus Cadila Company Information
6.3.2 Zydus Cadila Description and Business Overview
6.3.3 Zydus Cadila mRNA Drug Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Zydus Cadila mRNA Drug Product Portfolio
6.3.5 Zydus Cadila Recent Developments/Updates
6.4 Fosun Pharma
6.4.1 Fosun Pharma Company Information
6.4.2 Fosun Pharma Description and Business Overview
6.4.3 Fosun Pharma mRNA Drug Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Fosun Pharma mRNA Drug Product Portfolio
6.4.5 Fosun Pharma Recent Developments/Updates
6.5 CureVAC
6.5.1 CureVAC Company Information
6.5.2 CureVAC Description and Business Overview
6.5.3 CureVAC mRNA Drug Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 CureVAC mRNA Drug Product Portfolio
6.5.5 CureVAC Recent Developments/Updates
6.6 BioNtech
6.6.1 BioNtech Company Information
6.6.2 BioNtech Description and Business Overview
6.6.3 BioNtech mRNA Drug Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 BioNtech mRNA Drug Product Portfolio
6.6.5 BioNtech Recent Developments/Updates
6.7 AstraZeneca
6.7.1 AstraZeneca Company Information
6.7.2 AstraZeneca Description and Business Overview
6.7.3 AstraZeneca mRNA Drug Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 AstraZeneca mRNA Drug Product Portfolio
6.7.5 AstraZeneca Recent Developments/Updates
6.8 Janssen
6.8.1 Janssen Company Information
6.8.2 Janssen Description and Business Overview
6.8.3 Janssen mRNA Drug Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Janssen mRNA Drug Product Portfolio
6.8.5 Janssen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 mRNA Drug Industry Chain Analysis
7.2 mRNA Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 mRNA Drug Production Mode & Process Analysis
7.4 mRNA Drug Sales and Marketing
7.4.1 mRNA Drug Sales Channels
7.4.2 mRNA Drug Distributors
7.5 mRNA Drug Customer Analysis
8 mRNA Drug Market Dynamics
8.1 mRNA Drug Industry Trends
8.2 mRNA Drug Market Drivers
8.3 mRNA Drug Market Challenges
8.4 mRNA Drug Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global mRNA Drug Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global mRNA Drug Market Value by Target Cell (US$ Million), 2025 vs 2032
Table 3. Global mRNA Drug Market Value by Manufacturing Scale (US$ Million), 2025 vs 2032
Table 4. Global mRNA Drug Market Value by Application (US$ Million), 2025 vs 2032
Table 5. Global mRNA Drug Market Competitive Situation by Manufacturers in 2025
Table 6. Global mRNA Drug Sales (K Dose) of Key Manufacturers (2021–2026)
Table 7. Global mRNA Drug Sales Market Share by Manufacturers (2021–2026)
Table 8. Global mRNA Drug Revenue (US$ Million) by Manufacturers (2021–2026)
Table 9. Global mRNA Drug Revenue Share by Manufacturers (2021–2026)
Table 10. Global Market mRNA Drug Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 11. Global Key Players of mRNA Drug, Industry Ranking, 2023 vs 2024 vs 2025
Table 12. Global Key Manufacturers of mRNA Drug, Manufacturing Sites and Headquarters
Table 13. Global Key Manufacturers of mRNA Drug, Product Types and Applications
Table 14. Global Key Manufacturers of mRNA Drug, Date of Entry into the Industry
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global mRNA Drug Companies by Tier (Tier 1, Tier 2, Tier 3), based on mRNA Drug Revenue, 2025
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 18. Global mRNA Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 19. Global mRNA Drug Sales by Region (K Dose), 2021–2026
Table 20. Global mRNA Drug Sales Market Share by Region (2021–2026)
Table 21. Global mRNA Drug Sales by Region (K Dose), 2027–2032
Table 22. Global mRNA Drug Sales Market Share by Region (2027–2032)
Table 23. Global mRNA Drug Revenue by Region (US$ Million), 2021–2026
Table 24. Global mRNA Drug Revenue Market Share by Region (2021–2026)
Table 25. Global mRNA Drug Revenue by Region (US$ Million), 2027–2032
Table 26. Global mRNA Drug Revenue Market Share by Region (2027–2032)
Table 27. North America mRNA Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 28. North America mRNA Drug Sales by Country (K Dose), 2021–2026
Table 29. North America mRNA Drug Sales by Country (K Dose), 2027–2032
Table 30. North America mRNA Drug Revenue by Country (US$ Million), 2021–2026
Table 31. North America mRNA Drug Revenue by Country (US$ Million), 2027–2032
Table 32. Europe mRNA Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 33. Europe mRNA Drug Sales by Country (K Dose), 2021–2026
Table 34. Europe mRNA Drug Sales by Country (K Dose), 2027–2032
Table 35. Europe mRNA Drug Revenue by Country (US$ Million), 2021–2026
Table 36. Europe mRNA Drug Revenue by Country (US$ Million), 2027–2032
Table 37. Asia Pacific mRNA Drug Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 38. Asia Pacific mRNA Drug Sales by Region (K Dose), 2021–2026
Table 39. Asia Pacific mRNA Drug Sales by Region (K Dose), 2027–2032
Table 40. Asia Pacific mRNA Drug Revenue by Region (US$ Million), 2021–2026
Table 41. Asia Pacific mRNA Drug Revenue by Region (US$ Million), 2027–2032
Table 42. Latin America mRNA Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 43. Latin America mRNA Drug Sales by Country (K Dose), 2021–2026
Table 44. Latin America mRNA Drug Sales by Country (K Dose), 2027–2032
Table 45. Latin America mRNA Drug Revenue by Country (US$ Million), 2021–2026
Table 46. Latin America mRNA Drug Revenue by Country (US$ Million), 2027–2032
Table 47. Middle East and Africa mRNA Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 48. Middle East and Africa mRNA Drug Sales by Country (K Dose), 2021–2026
Table 49. Middle East and Africa mRNA Drug Sales by Country (K Dose), 2027–2032
Table 50. Middle East and Africa mRNA Drug Revenue by Country (US$ Million), 2021–2026
Table 51. Middle East and Africa mRNA Drug Revenue by Country (US$ Million), 2027–2032
Table 52. Global mRNA Drug Sales (K Dose) by Type (2021–2026)
Table 53. Global mRNA Drug Sales (K Dose) by Type (2027–2032)
Table 54. Global mRNA Drug Sales Market Share by Type (2021–2026)
Table 55. Global mRNA Drug Sales Market Share by Type (2027–2032)
Table 56. Global mRNA Drug Revenue (US$ Million) by Type (2021–2026)
Table 57. Global mRNA Drug Revenue (US$ Million) by Type (2027–2032)
Table 58. Global mRNA Drug Revenue Market Share by Type (2021–2026)
Table 59. Global mRNA Drug Revenue Market Share by Type (2027–2032)
Table 60. Global mRNA Drug Price (US$/Dose) by Type (2021–2026)
Table 61. Global mRNA Drug Price (US$/Dose) by Type (2027–2032)
Table 62. Global mRNA Drug Sales (K Dose) by Application (2021–2026)
Table 63. Global mRNA Drug Sales (K Dose) by Application (2027–2032)
Table 64. Global mRNA Drug Sales Market Share by Application (2021–2026)
Table 65. Global mRNA Drug Sales Market Share by Application (2027–2032)
Table 66. Global mRNA Drug Revenue (US$ Million) by Application (2021–2026)
Table 67. Global mRNA Drug Revenue (US$ Million) by Application (2027–2032)
Table 68. Global mRNA Drug Revenue Market Share by Application (2021–2026)
Table 69. Global mRNA Drug Revenue Market Share by Application (2027–2032)
Table 70. Global mRNA Drug Price (US$/Dose) by Application (2021–2026)
Table 71. Global mRNA Drug Price (US$/Dose) by Application (2027–2032)
Table 72. Moderna Company Information
Table 73. Moderna Description and Business Overview
Table 74. Moderna mRNA Drug Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 75. Moderna mRNA Drug Product
Table 76. Moderna Recent Developments/Updates
Table 77. Pfizer Company Information
Table 78. Pfizer Description and Business Overview
Table 79. Pfizer mRNA Drug Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 80. Pfizer mRNA Drug Product
Table 81. Pfizer Recent Developments/Updates
Table 82. Zydus Cadila Company Information
Table 83. Zydus Cadila Description and Business Overview
Table 84. Zydus Cadila mRNA Drug Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 85. Zydus Cadila mRNA Drug Product
Table 86. Zydus Cadila Recent Developments/Updates
Table 87. Fosun Pharma Company Information
Table 88. Fosun Pharma Description and Business Overview
Table 89. Fosun Pharma mRNA Drug Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 90. Fosun Pharma mRNA Drug Product
Table 91. Fosun Pharma Recent Developments/Updates
Table 92. CureVAC Company Information
Table 93. CureVAC Description and Business Overview
Table 94. CureVAC mRNA Drug Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 95. CureVAC mRNA Drug Product
Table 96. CureVAC Recent Developments/Updates
Table 97. BioNtech Company Information
Table 98. BioNtech Description and Business Overview
Table 99. BioNtech mRNA Drug Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 100. BioNtech mRNA Drug Product
Table 101. BioNtech Recent Developments/Updates
Table 102. AstraZeneca Company Information
Table 103. AstraZeneca Description and Business Overview
Table 104. AstraZeneca mRNA Drug Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 105. AstraZeneca mRNA Drug Product
Table 106. AstraZeneca Recent Developments/Updates
Table 107. Janssen Company Information
Table 108. Janssen Description and Business Overview
Table 109. Janssen mRNA Drug Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 110. Janssen mRNA Drug Product
Table 111. Janssen Recent Developments/Updates
Table 112. Key Raw Materials Lists
Table 113. Raw Materials Key Suppliers Lists
Table 114. mRNA Drug Distributors List
Table 115. mRNA Drug Customers List
Table 116. mRNA Drug Market Trends
Table 117. mRNA Drug Market Drivers
Table 118. mRNA Drug Market Challenges
Table 119. mRNA Drug Market Restraints
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
Table 123. Authors List of This Report
List of Figures
Figure 1. Product Picture of mRNA Drug
Figure 2. Global mRNA Drug Market Value by Type (US$ Million), 2021–2032
Figure 3. Global mRNA Drug Market Share by Type: 2025 & 2032
Figure 4. Prophylactic Vaccine (Infectious Disease) Product Picture
Figure 5. Therapeutic Vaccine (Cancer) Product Picture
Figure 6. Global mRNA Drug Market Value by Target Cell (US$ Million), 2021–2032
Figure 7. Global mRNA Drug Market Share by Target Cell: 2025 vs 2032
Figure 8. Intramuscular (Dendritic Cell) mRNA Product Picture
Figure 9. Intravenous (Liver-targeted) mRNA Product Picture
Figure 10. Intradermal (Skin APC) mRNA Product Picture
Figure 11. Inhalation (Lung epithelial) mRNA Product Picture
Figure 12. Global mRNA Drug Market Value by Manufacturing Scale (US$ Million), 2021–2032
Figure 13. Global mRNA Drug Market Share by Manufacturing Scale: 2025 vs 2032
Figure 14. Lab-scale (Preclinical, <1g) Product Picture
Figure 15. Pilot-scale (Phase I/II, 1-100g) Product Picture
Figure 16. Commercial-scale (Phase III/Market, >100g) Product Picture
Figure 17. Global mRNA Drug Market Value by Application (US$ Million), 2021–2032
Figure 18. Global mRNA Drug Market Share by Application: 2025 & 2032
Figure 19. Pharmaceutical Companies
Figure 20. Medical Institutions
Figure 21. Others
Figure 22. Global mRNA Drug Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 23. Global mRNA Drug Market Size (US$ Million), 2021–2032
Figure 24. Global mRNA Drug Sales (K Dose), 2021–2032
Figure 25. Global mRNA Drug Average Price (US$/Dose), 2021–2032
Figure 26. mRNA Drug Report Years Considered
Figure 27. mRNA Drug Sales Share by Manufacturers in 2025
Figure 28. Global mRNA Drug Revenue Share by Manufacturers in 2025
Figure 29. Top 5 and Top 10 Global mRNA Drug Players: Market Share by Revenue in mRNA Drug in 2025
Figure 30. mRNA Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 31. Global mRNA Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 32. North America mRNA Drug Sales Market Share by Country (2021–2032)
Figure 33. North America mRNA Drug Revenue Market Share by Country (2021–2032)
Figure 34. United States mRNA Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Canada mRNA Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Europe mRNA Drug Sales Market Share by Country (2021–2032)
Figure 37. Europe mRNA Drug Revenue Market Share by Country (2021–2032)
Figure 38. Germany mRNA Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. France mRNA Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. U.K. mRNA Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Italy mRNA Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Russia mRNA Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Asia Pacific mRNA Drug Sales Market Share by Region (2021–2032)
Figure 44. Asia Pacific mRNA Drug Revenue Market Share by Region (2021–2032)
Figure 45. China mRNA Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Japan mRNA Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. South Korea mRNA Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. India mRNA Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Australia mRNA Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. China Taiwan mRNA Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Southeast Asia mRNA Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Latin America mRNA Drug Sales Market Share by Country (2021–2032)
Figure 53. Latin America mRNA Drug Revenue Market Share by Country (2021–2032)
Figure 54. Mexico mRNA Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Brazil mRNA Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Argentina mRNA Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. Middle East and Africa mRNA Drug Sales Market Share by Country (2021–2032)
Figure 58. Middle East and Africa mRNA Drug Revenue Market Share by Country (2021–2032)
Figure 59. Turkey mRNA Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 60. Saudi Arabia mRNA Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 61. UAE mRNA Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 62. Global Sales Market Share of mRNA Drug by Type (2021–2032)
Figure 63. Global Revenue Market Share of mRNA Drug by Type (2021–2032)
Figure 64. Global mRNA Drug Price (US$/Dose) by Type (2021–2032)
Figure 65. Global Sales Market Share of mRNA Drug by Application (2021–2032)
Figure 66. Global Revenue Market Share of mRNA Drug by Application (2021–2032)
Figure 67. Global mRNA Drug Price (US$/Dose) by Application (2021–2032)
Figure 68. mRNA Drug Value Chain
Figure 69. Channels of Distribution (Direct Vs Distribution)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
